[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PA8790101A1 - Derivados de aminoalquilazol como antagonistas de histamina-3 - Google Patents

Derivados de aminoalquilazol como antagonistas de histamina-3

Info

Publication number
PA8790101A1
PA8790101A1 PA20088790101A PA8790101A PA8790101A1 PA 8790101 A1 PA8790101 A1 PA 8790101A1 PA 20088790101 A PA20088790101 A PA 20088790101A PA 8790101 A PA8790101 A PA 8790101A PA 8790101 A1 PA8790101 A1 PA 8790101A1
Authority
PA
Panama
Prior art keywords
histamine
aminoalquilazol
antagonists
derivatives
affected
Prior art date
Application number
PA20088790101A
Other languages
English (en)
Inventor
Jonathan Laird Gross
Albert Jean Robichaud
Alessandro Mazzacani
Marla Jean Williams
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8790101A1 publication Critical patent/PA8790101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE FÓRMULA 1:Y EL USO DE ESTE PARA EL TRATAMIENTO DE UN TRASTORNO DEL SISTEMA NERVIOSO CENTRAL RELACIONADO CON O AFECTADO POR EL RECEPTOR DE HISTAMINA-3.
PA20088790101A 2007-07-16 2008-07-16 Derivados de aminoalquilazol como antagonistas de histamina-3 PA8790101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95974107P 2007-07-16 2007-07-16

Publications (1)

Publication Number Publication Date
PA8790101A1 true PA8790101A1 (es) 2009-02-09

Family

ID=39708793

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088790101A PA8790101A1 (es) 2007-07-16 2008-07-16 Derivados de aminoalquilazol como antagonistas de histamina-3

Country Status (10)

Country Link
US (1) US7803825B2 (es)
EP (1) EP2170875A1 (es)
JP (1) JP2010533725A (es)
AR (1) AR067549A1 (es)
CA (1) CA2693138A1 (es)
CL (1) CL2008002088A1 (es)
PA (1) PA8790101A1 (es)
PE (1) PE20090812A1 (es)
TW (1) TW200920356A (es)
WO (1) WO2009012252A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100016609A1 (en) * 2008-07-15 2010-01-21 Wyeth Methods for the preparation of azole compounds
KR101804749B1 (ko) * 2009-06-26 2017-12-05 사노피 히스타민 ｈ3 수용체 길항제의 신규 푸마레이트 염
MX2012000763A (es) * 2009-07-15 2012-02-08 Janssen Pharmaceuticals Inc Derivados sustituidos de triazol e imidazol como moduladores de la gamma secretasa.
US20120208827A1 (en) * 2009-10-27 2012-08-16 Glaxosmithkline Llc Benzimidazoles as fatty acid synthase inhibitors
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN103570705B (zh) * 2012-07-18 2017-01-25 中国医学科学院医药生物技术研究所 取代的n‑((1＇,3＇‑杂唑‑4＇‑基)‑甲基)‑4‑苯甲酰基六氢吡啶类化合物及其用途
EP3429355B1 (de) 2016-03-15 2020-02-05 Bayer CropScience AG Substituierte sulfonylamide zur bekämpfung tierischer schädlinge
AU2021324684A1 (en) * 2020-08-11 2023-04-20 Board Of Trustees Of Michigan State University Proteasome enhancers and uses thereof
KR20230113192A (ko) * 2022-01-21 2023-07-28 재단법인 한국파스퇴르연구소 항박테리아 활성 옥사졸 유도체 화합물 및 이의 의약 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4168853A (en) * 1977-06-08 1979-09-25 Vetco, Inc. Shiftable ring gasket retainer for flanged connectors
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US4166853A (en) 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
ATE219766T1 (de) 1993-04-07 2002-07-15 Otsuka Pharma Co Ltd N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE69819539T2 (de) * 1997-05-01 2004-09-30 Eli Lilly And Co., Indianapolis Antithrombotische mittel
WO2001042224A1 (en) 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
ATE430730T1 (de) 2000-03-31 2009-05-15 Ortho Mcneil Pharm Inc Phenyl-substituierte indole als h3 histaminrezeptorantagonisten
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
IL164302A0 (en) 2002-03-29 2005-12-18 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors
WO2004081011A1 (en) 2003-03-14 2004-09-23 Avidex Limited Immunomodulating heterocyclic compounds
DE602005003951T4 (de) * 2004-05-14 2012-10-11 Millennium Pharmaceuticals, Inc. Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
DE602005014786D1 (de) 2004-07-26 2009-07-16 Lilly Co Eli Oxazolderivate als histamin-h3-rezeptor-wirkstoffe, deren herstellung und therapeutische verwendung
ES2534605T3 (es) 2004-08-23 2015-04-24 Eli Lilly And Company Agentes receptores de la histamina H3, preparación y usos terapéuticos
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
JP2008526895A (ja) * 2005-01-21 2008-07-24 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なイミダゾールおよびベンゾイミダゾール誘導体
JP2008537953A (ja) 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
JP2009531320A (ja) 2006-03-20 2009-09-03 グラクソ グループ リミテッド Ａｍｐａ受容体を強化する化合物および医薬におけるその使用
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Also Published As

Publication number Publication date
US20090023707A1 (en) 2009-01-22
AR067549A1 (es) 2009-10-14
PE20090812A1 (es) 2009-06-14
CA2693138A1 (en) 2009-01-22
CL2008002088A1 (es) 2008-09-05
US7803825B2 (en) 2010-09-28
WO2009012252A1 (en) 2009-01-22
JP2010533725A (ja) 2010-10-28
TW200920356A (en) 2009-05-16
EP2170875A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
PA8795701A1 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
GT200500185A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ECSP099553A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides
CR20140085A (es) Inhibidores de pde10 de pirimidina
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
CO6341625A2 (es) Derivados de indol como agentes anticáncer
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de
AR073708A1 (es) Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
CU20100047A7 (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3
CU20100045A7 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3